News and Trends 16 Oct 2017 Biotech Power-Couple Sees Positive Phase II Results For Inflammatory Disease Drug Regeneron and Sanofi’s drug, dupilumab, has met primary and secondary endpoints for the treatment of eosinophilic esophagitis. The biotech-biopharma giants have announced that their candidate, Dupilumab, demonstrated good efficacy during a Phase II trial. The drug is designed for use against eosinophilic esophagitis, a nasty inflammatory disease of the esophagus that makes it difficult to swallow. […] October 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 Swiss Genomics Firm, Biogen and Microsoft Team Up to Treat Multiple Sclerosis BC Platforms and Microsoft will be working with Biogen and the Accelerated Cure Project to study the genetics of multiple sclerosis and accelerate research. The Swiss firm BC Platforms has built a platform to facilitate access to and analysis of large volumes of genomic and clinical data. Since September, the company has been collaborating with Microsoft, […] October 16, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 French Biotech Lifted by €7M Series A to Develop New Antibiotics Antabio has taken a step towards tackling antibiotic resistance by securing a €7.3M Series A. The funding will accelerate the company’s candidate through a Phase I clinical trial. Antabio is a French biopharma that focuses on one of the world’s biggest crises – antibiotic resistance. The company has raised €7.3M in Series A of fundraising, which it will use to […] October 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 German Drug to Stop the Progression of Alzheimer’s Enters Phase IIb Probiodrug is ready to start a Phase IIb trial with an Alzheimer’s drug that prevents the formation of Aβ plaques before the disease progresses. The German biotech Probiodrug is getting ready to start two Phase II trials to study the safety and efficacy of its candidate PQ912, a drug designed to intervene in the early stages of […] October 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 Interview: On the Future of iPS Cells and why Partnering is so Important in this Field In our first part of the interview with Dr David Hallett, Executive Vice President at Evotec, we discussed the uniqueness of Induced Pluripotent Stem Cells (iPS Cells), novel developments occurring in iPS Cell research, and the challenges researchers face. Let us have a short recap of what we have learned so far: iPS Cells were […] October 16, 2017 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 New Stem Cells Could Take Cell Research and Therapies to the Next Level British researchers have created a new type of stem cell in mice. It has even greater potential than current cell lines in research and in the clinic. Stem cells have huge potential in research and therapeutics and overcome the limitations of current cell lines – embryonic and induced pluripotent stem cells. Findings published in Nature report that researchers at […] October 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 16 Oct 2017 Meet the Former Banker at the Helm of Denmark’s Healthcare Giant, Novo Holdings Kasim Kutay has ridden the biotech investment wave. First, he helped build Morgan Stanley’s European healthcare group, then did the same at Moelis & Co and now he heads Novo Holdings, the majority shareholder of Danish household biotech names NovoZymes and Novo Nordisk. I asked him about the company’s healthcare investment strategy and his CEO […] October 16, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 14 Oct 2017 Art and Biology Meet at Nonhuman Networks Exhibition in Berlin The exhibition Nonhuman Networks at Art Laboratory Berlin invites us to connect with other organisms and rethink our relationship with the environment. For those of us living in the Western world, our whole culture seems to revolve almost exclusively around ourselves. Despite having evolved within an ecosystem with a huge and fascinating diversity, we tend […] October 14, 2017 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 13 Oct 2017 German Biotech Gets €47M To Treat Painful Inflammatory Disease InflaRx has raised $55M (€47M) in a Series D fundraising in order to get its lead anti-inflammatory drug, IFX-1, through late-stage development. A year after its €31M Series C, InflaRx is closing a Series D round. The company has raised a total of $55M (€47M) from a team of US investors co-led by Bain Capital Life Sciences, […] October 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2017 Why Might Biotechs Lose Easy Access to Scientific Papers? Five publishers have ordered ResearchGate to take down articles. Researchers might continue to get around the paywall with Sci-Hub and other initiatives. ResearchGate, described as ‘Facebook for scientists’, has over 13 million members. It has raised more than $80M (€68M) from investors including Bill Gates and the Wellcome Trust. But, five scientific publishers including Elsevier and Wiley have clubbed […] October 13, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2017 Sanofi Invests €170M in French Facilities to Expand Flu Vaccine Supply Sanofi Pasteur will expand its main vaccine manufacturing site to increase distribution of its quadrivalent flu vaccine VaxigripTetra around the world. Sanofi will invest €170M in expanding its vaccine production facilities in Val de Reuil, France, which also hosts its global vaccine distribution center, from which it currently ships 900 million vaccine doses a year. The company plans to complete the expansion by […] October 13, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 13 Oct 2017 This French Biotech is Taking On CNS Diseases of the Young and the Elderly This week we’re in Castres in the South of France to visit Neurolixis. This biotech is taking on diseases of the CNS, such as Parkinson’s, depression and schizophrenia. Mission: Neurolixis is tackling CNS and mood diseases, a number of which lack effective treatment options at the moment. The biotech currently has two candidate drugs undergoing […] October 13, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email